Roche announced on 16 March 2026 an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of NVIDIA accelerated computing and AI. The infrastructure features 2,176 high-performance GPUs on premises across the United States and Europe, and Roche's combined on-premise and cloud GPU infrastructure now exceeds 3,500 Blackwell GPUs. Roche describes this as the greatest announced GPU footprint available to a pharmaceutical company and as the pharmaceutical industry's largest announced hybrid-cloud AI factory.
"In healthcare, time is the most critical variable; every day saved means a life-changing medicine or diagnostic reaches a patient sooner," said Wafaa Mamilli, Roche's Chief Digital and Technology Officer. Mamilli said the AI factory combines world-class computing power with Roche's scientific expertise to embed AI across the entire value chain, from discovery to development, manufacturing and commercialisation.
The expansion marks the next phase of a strategic collaboration with NVIDIA that started in 2023. Roche's AI factory is a high-performance supercomputing platform embedded across the value chain and designed to accelerate the development of diagnostics solutions and therapeutics. In R&D, the NVIDIA BioNeMo platform enhances Roche's Lab-in-the-Loop, where biological and chemistry experiments are connected with Roche's AI models, which helps scientists test hypotheses at scale. In manufacturing, digital twins, which are virtual replicas of production lines powered by NVIDIA Omniverse libraries, allow engineers to optimize processes and factory designs. In diagnostics, accelerated computing and NVIDIA Parabricks software enable insights across vast datasets. In digital pathology, the technologies scan a large number of images to detect subtle disease patterns. In digital health, Roche uses NVIDIA NeMo Guardrails to ensure safe and reliable healthcare-grade conversational AI.
Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development, said the AI factory provides the computational power needed to continue to scale the Lab-in-the-Loop strategy, so that "our scientists can build more sophisticated predictive frontier models and further shorten the path from biological insight to life-saving medicine."
Roche calls the implementation of the AI factory a cornerstone of its broader digital transformation, with AI designed to augment or complement human expertise and access to supercomputing capabilities extended across the organisation.